← All trials
NCT05519085
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2022
- Primary completion
- Nov 3, 2025
- Completion date
- Nov 30, 2033
- First posted
- Aug 29, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 760
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CelgeneLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.